Literature DB >> 30238792

The economic and humanistic burden of patients in receipt of current available therapies for nAMD.

Dena H Jaffe1, Wing Chan2, Vladimir Bezlyak3, Adrian Skelly3.   

Abstract

AIM: To determine the economic and humanistic burden of neovascular age-related macular degeneration (nAMD) in a cohort of patients treated with anti-VEGF in Europe and the US. PATIENTS &
METHODS: 79 respondents from the EU and 63 from the US with a self-reported diagnosis of nAMD and in current receipt of treatment, as reported in an international, general population survey, were compared with non-nAMD controls.
RESULTS: Anti-VEGF-treated nAMD patients in the EU had a greater utilization of healthcare resources, poorer quality of life and greater overall activity impairment versus non-nAMD controls. In the US cohort, treated nAMD patients had significantly greater resource utilization for ophthalmologist visits only.
CONCLUSION: The burden of care associated with nAMD on EU and US healthcare systems, and on patients who are in receipt of nAMD therapy, is significant and likely to be unsustainable.

Entities:  

Keywords:  NHWS; age-related macular degeneration; resource utilization; treatment burden

Mesh:

Substances:

Year:  2018        PMID: 30238792     DOI: 10.2217/cer-2018-0058

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  10 in total

Review 1.  Retinal Diseases: The Next Frontier in Pharmacodelivery.

Authors:  Assaf Ben-Arzi; Rita Ehrlich; Ron Neumann
Journal:  Pharmaceutics       Date:  2022-04-21       Impact factor: 6.525

2.  Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)-a phase III, prospective, multicentre, randomized study: design and methods.

Authors:  Leonard M Coulibaly; Stefan Sacu; Philipp Fuchs; Hrvoje Bogunovic; Georg Faustmann; Christian Unterrainer; Gregor S Reiter; Ursula Schmidt-Erfurth
Journal:  Eye (Lond)       Date:  2022-07-05       Impact factor: 4.456

3.  Burden of Illness in Geographic Atrophy: A Study of Vision-Related Quality of Life and Health Care Resource Use.

Authors:  Praveen J Patel; Focke Ziemssen; Eugene Ng; Anushini Muthutantri; David Silverman; Elizabeth A Tschosik; Ronald A Cantrell
Journal:  Clin Ophthalmol       Date:  2020-01-08

4.  Longitudinal Higher-Order OCT Assessment of Quantitative Fluid Dynamics and the Total Retinal Fluid Index in Neovascular AMD.

Authors:  Justis P Ehlers; Julie Clark; Atsuro Uchida; Natalia Figueiredo; Amy Babiuch; Katherine E Talcott; Leina Lunasco; Thuy K Le; Xiangyi Meng; Ming Hu; Jamie Reese; Sunil K Srivastava
Journal:  Transl Vis Sci Technol       Date:  2021-03-01       Impact factor: 3.283

5.  Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema.

Authors:  Takao Hirano; Yuichi Toriyama; Yoshihiro Takamura; Masahiko Sugimoto; Taiji Nagaoka; Yoshimi Sugiura; Fumiki Okamoto; Michiyuki Saito; Kousuke Noda; Shigeo Yoshida; Akihiro Ishibazawa; Osamu Sawada; Toshinori Murata
Journal:  Sci Rep       Date:  2021-02-24       Impact factor: 4.379

6.  Patient and retina specialists' preferences in neovascular age-related macular degeneration treatment. A discrete choice experiment.

Authors:  Roberto Gallego-Pinazo; Begoña Pina-Marin; Marta Comellas; Susana Aceituno; Laia Gómez-Baldó; Carles Blanch
Journal:  PLoS One       Date:  2021-12-31       Impact factor: 3.240

7.  Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting.

Authors:  Anne Rübsam; Saskia Rau; Daniel Pilger; Oliver Zeitz; Antonia M Joussen
Journal:  J Ophthalmol       Date:  2022-03-25       Impact factor: 1.909

8.  Prediction of treatment outcome in neovascular age-related macular degeneration using a novel convolutional neural network.

Authors:  Tsai-Chu Yeh; An-Chun Luo; Yu-Shan Deng; Yu-Hsien Lee; Shih-Jen Chen; Po-Han Chang; Chun-Ju Lin; Ming-Chi Tai; Yu-Bai Chou
Journal:  Sci Rep       Date:  2022-04-07       Impact factor: 4.379

9.  Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration.

Authors:  Semra Ozdemir; Eric Finkelstein; Jia Jia Lee; Issac Horng Khit Too; Kelvin Yi Chong Teo; Anna Chen Sim Tan; Tien Yin Wong; Gemmy Chui Ming Cheung
Journal:  PLoS One       Date:  2022-08-11       Impact factor: 3.752

10.  Early Canadian Real-World Experience with Brolucizumab in Anti-Vascular Endothelial Growth Factor-Experienced Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Chart Review.

Authors:  Michel Giunta; Louis-Pierre Gauvin Meunier; Donald Nixon; Jeff Steeves; Jason Noble
Journal:  Clin Ophthalmol       Date:  2022-08-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.